Long Shortz with LTR Pharma: ED nasal spray reachs new heights
Tylah Tully chats with LTR Pharma (ASX:LTP) executive chairman Lee Rodne about its successful pre-Investigational New Drug Application meeting with the US FDA, a major milestone in the development of its SPONTAN product.
It’s also gearing up to launch a new product Roxus, another nasal spray which could help gain access to the US healthcare market, valued over $6 billion dollars.
This video was developed in collaboration with LTR Pharma, a Stockhead advertiser at the time of publishing.
The interviews and discussions in this video are opinions only and not financial or investment advice. Viewers should obtain independent advice based on their own circumstances before making any financial decisions.
Explore More
-
Investor Guide: Health & Biotech FY2025 featuring Tim Boreham
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10